effect of ayurvedic formulation in high blood pressure

â??Evaluation of Ayurvedic Formulation- NIA/DG/2015/01 in the Sustainable Management of Newly Diagnosed Stage -1 Essential Hypertension.â??

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/10/016005

Enrollment

Registered

2018-10-12

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I10- Essential (primary) hypertension

Interventions

Intervention1: NIA/DG/2015/01 â?? GV: Convolvulus pleuricaulis Chois Whole plant 1 part Nordostachys jatamansi DC Rhizome 1 part Terminalia Arjuna Roxb. Bark 1 part Withania Somnifera Linn. Root 1 par

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who newly diagnosed as E.H.T (within 1-3 month duration) will be selected. 2. Mild to moderate grade patients of hypertension as per 7th JNC & WHO criteria will be include. 3. Isolated grade-1 Systolic or Diastolic hypertension

Exclusion criteria

Exclusion criteria: 1]Secondary hypertension. 2] Renal diseases, Diabetic Mellitus. 3] Pregnancy induced hypertension. 4] Drugs like Oral Contraceptive Pills, steroids

Design outcomes

Primary

Measure	Time frame
To assess role of NIA/DG/2015/01 formulation in Newly Diagnosed (1-3mnth) Stage-1 Essential Hypertension.Timepoint: To assess role of NIA/DG/2015/01 formulation in Newly Diagnosed (1-3mnth) Stage-1 Essential Hypertension.	—

Secondary

Measure	Time frame
To assess role of ayurevidic formulation in all stage of hypertensionTimepoint: 6 months	—

Countries

India

Contacts

Public ContactAnkita goyal

National institute of ayurveda

drankitagoyal91@gmail.com9024322311

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026